Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2019-08-02 Capital/Financing Update
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM POS EX
Capital/Financing Update Classification · 95% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT' filed with the SEC. It references the Securities Act of 1933 and is related to a registration statement for BioCardia, Inc. The content includes an exhibit index with various agreements, certificates, plans, and consents, typical of a registration statement amendment. The document is not a financial report, earnings release, or management discussion. It is a post-effective amendment to a registration statement, which is a type of capital raising filing. The document length is 11,828 characters, indicating it is a full filing, not a brief announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as Form S-1 and its amendments relate to securities registration and capital raising activities.
2019-08-02 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and requests the SEC to declare the Registration Statement effective at a specified date and time. The document is short (2088 characters) and is a formal request related to a capital raising filing (Form S-1). It does not contain financial statements or detailed financial data but is an update on a financing process. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to the registration and effectiveness of a securities offering.
2019-08-01 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-1 for BioCardia, Inc. It requests acceleration of the effective date of the registration statement and provides supplemental information about the preliminary prospectus distribution. The content is related to securities offering and underwriting process, not a financial report or earnings release. It is a regulatory communication related to capital raising but does not contain financial statements or detailed financial data. The document length is short (1698 characters) and it is a formal regulatory filing rather than a report or announcement of a report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-08-01 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to the registration of securities for a public offering, including details about the securities, underwriting, and offering terms. This type of filing is a capital markets document related to fundraising and securities issuance, not a financial report, management discussion, or governance document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2019-08-01 English
Regulatory Filings 2019
Regulatory Filings
2019-07-30 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission regarding a Registration Statement on Form S-1. It discusses the withdrawal of a request for acceleration of the effective date of the Registration Statement. The content is correspondence related to regulatory filing procedures and does not contain financial data, report content, or detailed financial disclosures. The document length is short (1059 characters), and it is a communication about a filing rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2019-07-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.